FibroGen Inc (NASDAQ:FGEN) insider K Peony Yu sold 2,851 shares of the stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $43.70, for a total value of $124,588.70. Following the sale, the insider now owns 162,086 shares of the company’s stock, valued at approximately $7,083,158.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

K Peony Yu also recently made the following trade(s):

  • On Monday, November 6th, K Peony Yu sold 7,500 shares of FibroGen stock. The shares were sold at an average price of $55.37, for a total value of $415,275.00.
  • On Wednesday, October 4th, K Peony Yu sold 15,000 shares of FibroGen stock. The shares were sold at an average price of $60.00, for a total value of $900,000.00.
  • On Monday, October 2nd, K Peony Yu sold 40,000 shares of FibroGen stock. The shares were sold at an average price of $54.63, for a total value of $2,185,200.00.

FibroGen Inc (FGEN) traded up $0.45 on Friday, hitting $42.40. The stock had a trading volume of 2,858,243 shares, compared to its average volume of 628,497. FibroGen Inc has a one year low of $19.25 and a one year high of $60.15. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in shares of FibroGen in the second quarter valued at $128,000. Oppenheimer Asset Management Inc. raised its holdings in shares of FibroGen by 112.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after acquiring an additional 2,336 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of FibroGen by 15.4% during the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 696 shares in the last quarter. BBR Partners LLC purchased a new stake in shares of FibroGen during the third quarter worth $299,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of FibroGen during the third quarter worth $299,000. Institutional investors own 57.43% of the company’s stock.

FGEN has been the subject of a number of recent research reports. Jefferies Group reiterated a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, September 12th. Mizuho restated a “hold” rating and issued a $61.00 target price on shares of FibroGen in a report on Thursday, November 9th. Stifel Nicolaus restated a “buy” rating and issued a $80.00 target price on shares of FibroGen in a report on Thursday, September 14th. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. FibroGen has an average rating of “Buy” and an average price target of $65.67.

ILLEGAL ACTIVITY WARNING: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/15/k-peony-yu-sells-2851-shares-of-fibrogen-inc-fgen-stock.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.